Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit https://www.TriConference.com/Precision-Medicine

Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit <a href="https://www.TriConference.com/Precision-Medicine" rel="nofollow" target="_blank">https://www.TriConference.com/Precision-Medicine</a>

Molecular Med Tri-Con 2020 | Artificial Intelligence in Precision Medicine

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field.For more information, please visit https://www.TriConference.com/Gene-Therapy

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field. For more information, please visit <a href="https://www.TriConference.com/Gene-Therapy" rel="nofollow" target="_blank">https://www.TriConference.com/Gene-Therapy</a>

Molecular Med TriCon 2019 | Gene Therapy for Rare Disorders

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell &amp; gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and moreFor more information, please visit https://www.ImmunogenicitySummit.com/Workshop

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell &amp; gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more For more information, please visit <a href="https://www.ImmunogenicitySummit.com/Workshop" rel="nofollow" target="_blank">https://www.ImmunogenicitySummit.com/Workshop</a>

Immunogenicity Summit 2019 | From Cell & Gene Therapy to Biostatistics

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health.For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health. For more information, please visit <a href="https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics" rel="nofollow" target="_blank">https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics</a>

Next Generation Dx 2019 | Launch a Paradigm Shift through an Innovative Diagnostic Test

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation &amp; growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead.For more information, please visit https://www.LiquidBiopsySummit.com/Programs

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation &amp; growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead. For more information, please visit <a href="https://www.LiquidBiopsySummit.com/Programs" rel="nofollow" target="_blank">https://www.LiquidBiopsySummit.com/Programs</a>

the Liquid Biopsy Summit 2019 | Reimagining Liquid Biopsy Applications with Epigenomics

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research. For more information, please visit <a href="https://www.MolecularDXEurope.com/Point-of-Care-Dx" rel="nofollow" target="_blank">https://www.MolecularDXEurope.com/Point-of-Care-Dx</a>

Molecular DX Europe 2019 | Using Point-of-Care Diagnostics to Advance a One Health Approach

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential.For more information, please visit https://www.TriConference.com/Digital-Pathology

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential. For more information, please visit <a href="https://www.TriConference.com/Digital-Pathology" rel="nofollow" target="_blank">https://www.TriConference.com/Digital-Pathology</a>

Molecular Med Tri-Con 2019 | Putting the AI in Wait

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently.For more information, please visit https://www.TriConference.com/Precision-Medicine

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently. For more information, please visit <a href="https://www.TriConference.com/Precision-Medicine" rel="nofollow" target="_blank">https://www.TriConference.com/Precision-Medicine</a>

Molecular Med Tri-Con 2019 | Real Precision Medicine is Starting with the Patient

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.For more information, please visit https://www.triconference.com/Companion-Diagnostics

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process. For more information, please visit <a href="https://www.triconference.com/Companion-Diagnostics" rel="nofollow" target="_blank">https://www.triconference.com/Companion-Diagnostics</a>

Molecular Med Tri-Con 2019 | Target the Tumor Mutational Burden and Pursue Harmonization

Jennifer Chadwick

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.

PEGS Boston 2019 | Jennifer Chadwick’s Story of Building a Creative and Authentic Career in Science

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.

CHI Podcasts

The field of immunotherapy is very exciting and holds great promise. This podcast will review limitations of monotherapy, and describe Dr. Curran’s approach for inducing an immune response through combination therapy.  He will explain how this approach different from existing approaches and how it uses new strategies to overcome common limitations. Advice will be shared for selecting immunotherapy combinations and review applications emerging in combination therapy that are not possible with monotherapy.For more information go to http://www.PEGSummit.com/

The field of immunotherapy is very exciting and holds great promise. This podcast will review limitations of monotherapy, and describe Dr. Curran’s approach for inducing an immune response through combination therapy. He will explain how this approach different from existing approaches and how it uses new strategies to overcome common limitations. Advice will be shared for selecting immunotherapy combinations and review applications emerging in combination therapy that are not possible with monotherapy. For more information go to <a href="http://www.PEGSummit.com/" rel="nofollow" target="_blank">http://www.PEGSummit.com/</a>

PEGS Boston 2015 | Identification and Translation of Optimal Immunotherapy Combinations

CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases. Discussion questions include:•	Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?)•	What are emerging and promising therapeutic targets within the UPR and why?•	What are some of the current challenges surrounding targeting the UPR?•	You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference?•	What are people within this space just now starting to think about? In other words, where will the greatest attention be over the next few years within this space?To learn more, visit http://www.DiscoveryOnTarget.com/

CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases. Discussion questions include: •	Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?) •	What are emerging and promising therapeutic targets within the UPR and why? •	What are some of the current challenges surrounding targeting the UPR? •	You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference? •	What are people within this space just now starting to think about? In other words, where will the greatest attention be over the next few years within this space? To learn more, visit <a href="http://www.DiscoveryOnTarget.com/" rel="nofollow" target="_blank">http://www.DiscoveryOnTarget.com/</a>

Discovery on Target 2015 | Targeting The Unfolded Protein Response

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30.  Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18.  Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider.  Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed.For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit <a href="http://www.HealthTech.com/Prenatal-Diagnostics/" rel="nofollow" target="_blank">http://www.HealthTech.com/Prenatal-Diagnostics/</a>

Advances in Prenatal Molecular Diagnostics 2015 | Cell-free DNA Prenatal Testing

A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs

Leveraging Health Information Exchange to Achieve Population Health Surveillance

This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people introducing new ADC products in the clinical setting; and some of the most exciting new developments and emerging applications for ADCs. He shares his thoughts on ADCs that target both cancer initiating cells and differentiated cancer cells and clinical results; escape mechanisms tumor cells use to avoid destruction by ADCs; how perception shifted over the last three –four years on ADCs; and how can ADCs be combined with immuno-oncology approaches.

PEGS Europe 2017 | The Next Generation of Antibody-Drug Conjugates (ADCs)

Amid Zand interviews Mr. John Warren of McDermott Will &amp; Emery on 23 September, 2014. Mr. Warren will be speaking at the Evidence-Based Reimbursement Summit, November 17 to 19, in Bethesda, MD. His talk will be focused on examining speed bumps and road blocks in Medicare payments for diagnostics.

EBRS 2014 | Impact of PAMA on the Molecular Diagnostics Market Environment

CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis.Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/

CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis. Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit <a href="http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/" rel="nofollow" target="_blank">http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/</a>

Tri-Con 2016 | Metabolomics for Sepsis: Predictive Biomarkers

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them. Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: http://www.SCOPESummit.com

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them. Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: <a href="http://www.SCOPESummit.com" rel="nofollow" target="_blank">http://www.SCOPESummit.com</a>

SCOPE 2018 | Clinical Trial Contracting Challenges

Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current research. Dr. Vora is speaking at the Advances in Prenatal Molecular Diagnostics conference, taking place November 28-29, 2017 in Cambridge, MA. For details, visit: http://www.Healthtech.com/Prenatal-Diagnostics/

Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current research. Dr. Vora is speaking at the Advances in Prenatal Molecular Diagnostics conference, taking place November 28-29, 2017 in Cambridge, MA. For details, visit: <a href="http://www.Healthtech.com/Prenatal-Diagnostics/" rel="nofollow" target="_blank">http://www.Healthtech.com/Prenatal-Diagnostics/</a>

Advances in Prenatal Molecular Diagnostics 2017 | Fetal Whole Exome Sequencing

Dr. John P. Wikswo of Vanderbilt University speaks to CHI on September 8, 2014. Dr. Wikswo will be a keynote speaker during the Engineering Functional 3D Models and Organotypic Culture Models for Toxicology conferences at the FAST Congress, November 17-19 in Boston, MA.Topics include the evolution of tissue- and organ-scale toxicology research, the need for microfluidics in biological physics to control systems, challenges with organs-on-a-chip efforts, the hermeneutic circle of biology and more.

Dr. John P. Wikswo of Vanderbilt University speaks to CHI on September 8, 2014. Dr. Wikswo will be a keynote speaker during the Engineering Functional 3D Models and Organotypic Culture Models for Toxicology conferences at the FAST Congress, November 17-19 in Boston, MA. Topics include the evolution of tissue- and organ-scale toxicology research, the need for microfluidics in biological physics to control systems, challenges with organs-on-a-chip efforts, the hermeneutic circle of biology and more.

FAST Congress 2014 | Understanding Drug Toxicity

A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine

Information Technology in Support of Genetics in the Clinic

Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference &amp; Expo, May 15-17, 2018 in Boston, Massachusetts.                                                                                                          Topics Questions Include:1)     Let’s touch upon your gene discovery work. What determines the disease genes and conditions you study, with an eye on clinical impact?2)     How does research on rare and orphan disease enhance our understanding of medicine overall?3)     While you zoom in on rare diseases for the sake of broader knowledge, you also look broadly or globally to answer local questions, liaising between academia and industry, and partnering with clinicians with a shared goal of enhancing patient care. What do both the research and clinical sides need to contribute to the process, and what challenges still need to be ironed out?For more information, please visit http://www.bio-itworldexpo.com/clinical-omics/

Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference &amp; Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Let’s touch upon your gene discovery work. What determines the disease genes and conditions you study, with an eye on clinical impact? 2) How does research on rare and orphan disease enhance our understanding of medicine overall? 3) While you zoom in on rare diseases for the sake of broader knowledge, you also look broadly or globally to answer local questions, liaising between academia and industry, and partnering with clinicians with a shared goal of enhancing patient care. What do both the research and clinical sides need to contribute to the process, and what challenges still need to be ironed out? For more information, please visit <a href="http://www.bio-itworldexpo.com/clinical-omics/" rel="nofollow" target="_blank">http://www.bio-itworldexpo.com/clinical-omics/</a>

Bio-IT World Expo 2018 | Gene Discovery and Clinical Impact

CHI chats with Raymond J. Langley, Ph.D., Associate Research Scientist, Lovelace Respiratory Research Institute. Dr. Langley discusses his current work on metabolomics risk analysis models for sepsis as well as the challenges associated with them and other developing technology.Dr. Langley is the chair for our Direct Detection for Sepsis session and our Novel Technologies and Approaches session at the Molecular Diagnostics for Infectious Disease conference at the 2015 Next-Generation Diagnostics Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

CHI chats with Raymond J. Langley, Ph.D., Associate Research Scientist, Lovelace Respiratory Research Institute. Dr. Langley discusses his current work on metabolomics risk analysis models for sepsis as well as the challenges associated with them and other developing technology. Dr. Langley is the chair for our Direct Detection for Sepsis session and our Novel Technologies and Approaches session at the Molecular Diagnostics for Infectious Disease conference at the 2015 Next-Generation Diagnostics Summit. For details, visit <a href="http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics" rel="nofollow" target="_blank">http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics</a>

Next Generation Dx Summit 2015 | Metabolomics for Infectious Disease: A Focus on Sepsis

Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community and more.  For more information, please visit http://www.NextGenerationDX.com/Reimbursement-Diagnostics/ and http://www.NextGenerationDX.com/Precision-Medicine/

Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community and more. For more information, please visit <a href="http://www.NextGenerationDX.com/Reimbursement-Diagnostics/" rel="nofollow" target="_blank">http://www.NextGenerationDX.com/Reimbursement-Diagnostics/</a> and <a href="http://www.NextGenerationDX.com/Precision-Medicine/" rel="nofollow" target="_blank">http://www.NextGenerationDX.com/Precision-Medicine/</a>

Next Generation DX Summit 2018 | the Value of NGS-based Diagnostic Testing for Lung Cancer Patients

The panelists describe what they will be covering during the panel discussion, which include third party payer requirements for clinical utility and funding sources. They will also review how the higher level of evidence will impact implementation, equity and access.

Next Generation Summit 2014 | Preview of the Panel Discussion on IMPLEMENTATION OF MOLECULAR TESTING

CHI chats with Ally Dering-Anderson, BA, Pharm.D., RP, FAAIM, who is a Clinical Assistant Professor of Pharmacy at the University of Nebraska College of Pharmacy. Ally discusses legal considerations, collaborative care agreements, training, and the changing role of pharmacies.Ally will present a regulatory update for point-of-care diagnostics in the community pharmacy market at the 2015 Next Generation Dx Summit. For details, visit http://www.NextGenerationDx.com/Pharmacy-Diagnostics

CHI chats with Ally Dering-Anderson, BA, Pharm.D., RP, FAAIM, who is a Clinical Assistant Professor of Pharmacy at the University of Nebraska College of Pharmacy. Ally discusses legal considerations, collaborative care agreements, training, and the changing role of pharmacies. Ally will present a regulatory update for point-of-care diagnostics in the community pharmacy market at the 2015 Next Generation Dx Summit. For details, visit <a href="http://www.NextGenerationDx.com/Pharmacy-Diagnostics" rel="nofollow" target="_blank">http://www.NextGenerationDx.com/Pharmacy-Diagnostics</a>

Next Generation Dx Summit 2015 | POC in the Pharmacy: Practical, Legal, and Future Perspectives

Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays for Biologics at the PEGS Summit this May 3-4 in Boston, MA!For more information, please visit http://www.PEGSummit.com/Bioassays-Conference/

Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays for Biologics at the PEGS Summit this May 3-4 in Boston, MA! For more information, please visit <a href="http://www.PEGSummit.com/Bioassays-Conference/" rel="nofollow" target="_blank">http://www.PEGSummit.com/Bioassays-Conference/</a>

PEGS Boston 2018 | Challenges and Opportunities in the Next Generation of Bioassays for Biologics

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for:· Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health· Developing novel endpoints based on an individual’s day-to-day experience· Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points· Optimizing study recruitment and protocol compliance through digital channelsFor more information, please visit http://www.Bio-ITWorld.com

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for: · Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health · Developing novel endpoints based on an individual’s day-to-day experience · Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points · Optimizing study recruitment and protocol compliance through digital channels For more information, please visit <a href="http://www.Bio-ITWorld.com" rel="nofollow" target="_blank">http://www.Bio-ITWorld.com</a>

Harnessing the power of Big Data and AI for faster, better, and more efficient studies

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward.For more information please visit http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward. For more information please visit <a href="http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/" rel="nofollow" target="_blank">http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/</a>

Molecular Diagnostics Europe 2018 | The Role of Epigenetics in Circulating Tumour Cells

The best podcasts on investing. For anyone interested in the stories in the investing industry, whether it's an interview with Ray Dalio or Ed Thorp to the writer of The Big Short. This topic includes the most fascinating stories from all the best investors. Add episodes you're interested into your queue below!

Best Investing Podcasts

The best podcasts about ourselves as well as the world through the lense of Science. Specific topics include things about our brain, emotions to biology, physics and more!